GO:0032904 negative regulation of nerve growth factor production

Nerve growth factor (NGF) is a secreted neurotrophin essential for the survival and function of sympathetic and sensory neurons, and it also acts as a key mediator of pain and inflammation. The production of NGF is tightly controlled at multiple levels, and its dysregulation contributes to a range of pathological states, from chronic pain to neurodegenerative disorders. GO:0032904, negative regulation of nerve growth factor production, captures the biological processes that reduce the frequency, rate, or extent of NGF production. This term is of significant interest to researchers studying neurobiology, immunology, and cancer biology, as it provides a framework for understanding how cells and tissues limit NGF output under physiological and pathological conditions [4,6]. Recent studies have highlighted the importance of negative regulation of NGF production in diverse contexts. For example, in osteoarthritic synovium, macrophages produce NGF, and local negative regulators may modulate this production to influence pain and joint damage. In leprosy, NGF levels correlate with IL-17 expression, suggesting a complex interplay between neurotrophins and inflammatory cytokines. Furthermore, negative regulators of angiogenesis, such as PEDF, have been shown to improve mitochondrial function in retinal pigment epithelial cells, indirectly linking to NGF regulation in ocular diseases. These findings underscore the need for precise experimental models to dissect the molecular mechanisms governing NGF production. This article provides a comprehensive overview of GO:0032904, integrating authoritative QuickGO data with real PubMed literature. We cover the definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods, including CRISPR-based approaches. By synthesizing this information, we aim to support researchers in designing experiments that causally test the role of candidate genes in negative regulation of NGF production.

GO:0032904, negative regulation of nerve growth factor production, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of nerve growth factor (NGF). This biological process encompasses molecular events that suppress the synthesis, processing, or secretion of NGF, a neurotrophin involved in neuronal survival, differentiation, and pain signaling. The term is a child of negative regulation of NGF production and is distinct from positive regulation or regulation of NGF production. It is used in gene ontology annotations to describe the roles of gene products that attenuate NGF output in various cellular contexts.

Negative regulation of NGF production is critical for maintaining tissue homeostasis and preventing pathological states associated with excessive NGF. NGF is a potent mediator of pain and inflammation, and its overproduction can lead to chronic pain syndromes and inflammatory damage. Conversely, insufficient NGF production is linked to neurodegeneration. Understanding the negative regulators of NGF production provides insights into disease mechanisms and identifies potential therapeutic targets. For instance, in osteoarthritic synovium, macrophages are a major source of NGF, and local negative regulators may offer avenues to modulate pain. In leprosy, the correlation between NGF and IL-17 suggests that negative regulation of NGF production may influence immune responses. Moreover, in exudative age-related macular degeneration, negative regulators of angiogenesis, such as PEDF, may indirectly affect NGF production and retinal health [6,7]. Thus, this GO term is central to neurobiology, immunology, and ophthalmology research.

The following genes and proteins have been implicated in the negative regulation of NGF production or related pathways, based on published literature.

The negative regulation of NGF production is itself subject to regulation by various signaling pathways. Inflammatory cytokines such as IL-17 can modulate NGF levels, as seen in leprosy, where NGF correlates with IL-17 expression. In osteoarthritic synovium, macrophages produce NGF, and local factors may suppress this production. The mTOR pathway, a central regulator of cell growth and metabolism, may integrate nutrient and stress signals to influence NGF production, as suggested by studies on PEDF and mitochondrial function in retinal pigment epithelial cells. Additionally, negative regulators of angiogenesis, such as PEDF, may affect NGF secretion in ocular tissues. However, the precise molecular mechanisms linking these pathways to NGF suppression require further investigation.

In osteoarthritis, NGF produced by macrophages in the synovium contributes to pain and inflammation. Negative regulation of NGF production is therefore a potential therapeutic strategy. Understanding which factors suppress NGF in this context could lead to new treatments for osteoarthritis pain. The correlation between NGF and IL-17 in leprosy further highlights the interplay between inflammation and NGF regulation.

Leprosy is a chronic infectious disease caused by Mycobacterium leprae, and NGF levels correlate with IL-17 expression in affected tissues. This suggests that negative regulation of NGF production may be part of the immune response to infection. Modulating NGF production could influence disease progression and nerve damage, a hallmark of leprosy.

Exudative AMD is characterized by abnormal angiogenesis, and negative regulators of angiogenesis are important therapeutic targets. PEDF, a negative regulator of angiogenesis, improves mitochondrial function in retinal pigment epithelial cells during oxidative stress. Since NGF can promote neuronal survival and angiogenesis, negative regulation of NGF production may be relevant to AMD pathology. However, direct evidence linking NGF suppression to AMD is limited and requires further study.

CREB3L1 promotes tumor growth and metastasis in anaplastic thyroid carcinoma by remodeling the tumor microenvironment. Although NGF is not the primary focus of that study, the tumor microenvironment often involves neurotrophins. Negative regulation of NGF production could be a mechanism by which tumor cells modulate innervation and immune cell infiltration. Further research is needed to establish a direct link.

RNA sequencing can quantify NGF mRNA levels and identify transcriptional changes in response to negative regulators. In studies of osteoarthritic synovium, RNA-seq of macrophages could reveal pathways that suppress NGF production. Similarly, in leprosy, RNA-seq of skin lesions may uncover links between IL-17 and NGF.

Measuring NGF protein levels by ELISA or Western blot is essential to confirm negative regulation at the protein level. In retinal pigment epithelial cells, PEDF effects on mitochondrial function and NGF secretion can be assessed by ELISA. In osteoarthritis, synovial fluid NGF levels can be quantified.

Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of NGF production. Such screens in NGF-producing cell lines (e.g., macrophages or neurons) could reveal genes whose loss increases NGF, indicating a negative regulatory role.

Immunohistochemistry and immunofluorescence can localize NGF and its regulators in tissues. In leprosy, co-staining of NGF and IL-17 can reveal spatial correlations. In AMD, retinal imaging of PEDF and NGF may elucidate their relationship.

Researchers studying negative regulation of nerve growth factor production-related genes often need to determine whether a candidate gene is causally involved in suppressing NGF. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout to overexpression and library screening.

GO:0032904, negative regulation of nerve growth factor production, is a critical biological process with broad implications for pain, inflammation, neurodegeneration, and cancer. Despite its importance, the molecular mechanisms and key regulators remain incompletely understood. Leveraging CRISPR-based models and advanced omics technologies will accelerate the discovery of novel negative regulators and their therapeutic potential. EDITGENE is committed to supporting this research with robust gene editing and screening services.